CN104350051B - 用于糖尿病的异噁唑治疗剂 - Google Patents

用于糖尿病的异噁唑治疗剂 Download PDF

Info

Publication number
CN104350051B
CN104350051B CN201280057505.0A CN201280057505A CN104350051B CN 104350051 B CN104350051 B CN 104350051B CN 201280057505 A CN201280057505 A CN 201280057505A CN 104350051 B CN104350051 B CN 104350051B
Authority
CN
China
Prior art keywords
substituted
hydrogen
och
insulin
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280057505.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104350051A (zh
Inventor
埃尔哈吉·迪乌姆
杰伊·施奈德
道格·弗朗茨
赫克托·阿吉拉尔
梅拉妮·科布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN104350051A publication Critical patent/CN104350051A/zh
Application granted granted Critical
Publication of CN104350051B publication Critical patent/CN104350051B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280057505.0A 2011-11-23 2012-11-21 用于糖尿病的异噁唑治疗剂 Expired - Fee Related CN104350051B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161563419P 2011-11-23 2011-11-23
US61/563,419 2011-11-23
US201161566056P 2011-12-02 2011-12-02
US61/566,056 2011-12-02
PCT/US2012/066346 WO2013078376A2 (en) 2011-11-23 2012-11-21 Isoxazole treatments for diabetes

Publications (2)

Publication Number Publication Date
CN104350051A CN104350051A (zh) 2015-02-11
CN104350051B true CN104350051B (zh) 2017-03-08

Family

ID=48470419

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280057505.0A Expired - Fee Related CN104350051B (zh) 2011-11-23 2012-11-21 用于糖尿病的异噁唑治疗剂

Country Status (9)

Country Link
US (2) US8722716B2 (https=)
EP (1) EP2782913A4 (https=)
JP (1) JP6190819B2 (https=)
CN (1) CN104350051B (https=)
AU (2) AU2012340622A1 (https=)
CA (1) CA2854039A1 (https=)
IL (1) IL232566A0 (https=)
MX (1) MX2014006286A (https=)
WO (1) WO2013078376A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10443044B2 (en) 2014-04-17 2019-10-15 Ips Heart Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
US20150297638A1 (en) * 2014-04-17 2015-10-22 Muhammad Ashraf Chemically induced pluripotent stem cells for safe therapeutic applications
JP2019503697A (ja) * 2016-02-04 2019-02-14 ネステク ソシエテ アノニム 明細書
JP6835899B2 (ja) * 2018-03-29 2021-02-24 株式会社 バイオミメティクスシンパシーズ Ｕｃｐ１発現細胞の培養方法
CN116270635B (zh) * 2021-12-13 2025-06-17 清华大学 杂环化合物用于减轻化疗药物引起的不良反应的用途
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US20060089398A1 (en) * 2003-03-19 2006-04-27 Gang Liu Isoxazole carboxamide derivatives as ghrelin receptor modulators
CN101035536A (zh) * 2004-10-08 2007-09-12 诺瓦提斯公司 有机化合物的组合
US20090036451A1 (en) * 2006-10-13 2009-02-05 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3542827B2 (ja) 1994-07-15 2004-07-14 帝国臓器製薬株式会社 新規な５−置換イソキサゾール−３−カルボン酸アミド誘導体
US20060036451A1 (en) 2004-08-10 2006-02-16 Lundberg Steven W Patent mapping
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2009147990A1 (ja) * 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US20060089398A1 (en) * 2003-03-19 2006-04-27 Gang Liu Isoxazole carboxamide derivatives as ghrelin receptor modulators
CN101035536A (zh) * 2004-10-08 2007-09-12 诺瓦提斯公司 有机化合物的组合
US20090036451A1 (en) * 2006-10-13 2009-02-05 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis

Also Published As

Publication number Publication date
AU2017202134A1 (en) 2017-04-20
IL232566A0 (en) 2014-06-30
JP6190819B2 (ja) 2017-08-30
EP2782913A2 (en) 2014-10-01
WO2013078376A3 (en) 2014-12-04
US20140315966A1 (en) 2014-10-23
WO2013078376A2 (en) 2013-05-30
JP2015510493A (ja) 2015-04-09
MX2014006286A (es) 2014-10-24
EP2782913A4 (en) 2015-10-28
CN104350051A (zh) 2015-02-11
AU2012340622A1 (en) 2014-05-22
US9221800B2 (en) 2015-12-29
US20130178506A1 (en) 2013-07-11
CA2854039A1 (en) 2013-05-30
US8722716B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
CN104350051B (zh) 用于糖尿病的异噁唑治疗剂
EP3596053B1 (en) Farnesoid x receptor agonists and uses thereof
CA2677264C (en) Compositions and methods for the treatment of metabolic disorders
US9212179B2 (en) Compositions and methods for the treatment of metabolic disorders
US11247970B2 (en) Selective inhibition of gluconeogenic activity
TW200918049A (en) Compounds useful as medicaments
CA3231566A1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
US20160128985A1 (en) Methods and Compositions for the Treatment of Body Weight Related Disorders
US20150307501A1 (en) Compositions and Methods for the Treatment of Metabolic and Related Disorders
US20160257675A1 (en) Compositions and methods for the treatment of metabolic disorders
EP3801515B1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
EP3664806B1 (en) 3-PHENYL-PYRAZOLO[1,5-A]PYRIMIDINE-5-CARBOXILIC ACID DERIVATIVES AS APELIN (APJ) RECEPTOR AGONISTS FOR THE TREATMENT OF CARDIOVASCULAR, METABOLIC, CNS, OR INFECTIOUS DISEASES OR DISORDERS
WO2019201752A1 (en) Pharmaceutical composition, methods for treating and uses thereof
CA2666090C (en) Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes
JP7224303B2 (ja) 薬剤、組成物、及びそれに関連する方法
CN102786517B (zh) Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物
CN115087643B (zh) 稠和杂环类化合物及其制备方法和医药用途
CN113648318B (zh) 增强细胞产热和治疗疾病的应用
EP1853258A2 (en) Medicaments
WO2022109292A1 (en) Methods and materials for inhibiting cb1 activity
WO2020115009A1 (en) LPAAT-β INHIBITORS FOR TREATMENT OF CANCER
NZ723402A (en) Compositions of selenoorganic compounds and methods of use thereof
HK1226065B (zh) 连接物关联激酶1的抑制剂、包含其的组合物、及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170308

Termination date: 20181121

CF01 Termination of patent right due to non-payment of annual fee